/term/capex-to-revenue/BOM:539730 Fredun Pharmaceuticals (BOM:539730) Capex-to-Revenue
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fredun Pharmaceuticals Ltd (BOM:539730) » Definitions » Capex-to-Revenue

Fredun Pharmaceuticals (BOM:539730) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Fredun Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Fredun Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹1,172.14 Mil.

Hence, Fredun Pharmaceuticals's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Fredun Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Fredun Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fredun Pharmaceuticals Capex-to-Revenue Chart

Fredun Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.02 0.04 0.02

Fredun Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fredun Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fredun Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fredun Pharmaceuticals's Capex-to-Revenue falls into.



Fredun Pharmaceuticals Capex-to-Revenue Calculation

Fredun Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-76.391) / 3465.769
=0.02

Fredun Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 1172.142
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fredun Pharmaceuticals  (BOM:539730) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Fredun Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fredun Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fredun Pharmaceuticals (BOM:539730) Business Description

Traded in Other Exchanges
N/A
Address
Ganpatrao Kadam Marg, 11th Floor, Urmi Estate, Lower Parel (West), Mumbai, MH, IND, 400013
Fredun Pharmaceuticals Ltd is an India based company engaged in the business of pharmaceuticals and healthcare. The company manufactures pharmaceutical formulations, nutraceuticals, herbal supplements, and dietary supplements. In addition, it also manufactures animal healthcare products through its group companies. It sells its products in India and also exports its formulations as branded generics to international countries.

Fredun Pharmaceuticals (BOM:539730) Headlines

No Headlines